Shownotes
It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval and a rough week for two RNA-based rare disease programs at Novartis.

